A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

PHASE1CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Healthy VolunteerAtopic DermatitisHidradenitis Suppurativa
Interventions
DRUG

KT-474/Placebo

KT-474 or matching placebo oral tablet(s)

DRUG

KT-474

KT-474 oral tablet(s)

Trial Locations (14)

22024

Research Centers of America, Hollywood

33021

Encore Medical Research, LLC. - Hollywood, Hollywood

33331

Encore Medical Research, LLC. - Weston, Weston

33436

Encore Medical Research, LLC. - Boynton Beach, Boynton Beach

64064

Dermatology and Skin Cancer Center of Lee's Summit, Lee's Summit

66211

Dermatology and Skin Cancer Center of Leawood, Leawood

66223

Dermatology and Skin Cancer Center of Overland Park, Overland Park

78613

U.S. Dermatology Partners Cedar Park, Cedar Park

78759

U.S. Dermatology Partners Jollyville, Austin

85006

Medical Dermatology Specialists, Phoenix

85018

Southwest Skin Specialists 32nd St, Phoenix

85028

Southwest Skin Specialists Tatum, Phoenix

85375

Beatrice Keller Clinic, Sun City West

07410

TKL Research, Fair Lawn

Sponsors
All Listed Sponsors
lead

Kymera Therapeutics, Inc.

INDUSTRY